Belmont, MANCT06816329Now EnrollingIRB Ready

Major Depressive Disorder Clinical Trial in Belmont, MA

Access cutting-edge major depressive disorder treatment through this clinical trial at a research site in Belmont. Study-provided care at no cost to qualified participants.

Sponsored by Mclean Hospital

Quick Self-Assessment

See if you qualify for this Belmont location

Preparing your pre-screening questions…

Expert Care in Belmont

Access major depressive disorder specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related major depressive disorder treatment provided free

Apply for This Belmont Location

Check if you qualify for this major depressive disorder clinical trial in Belmont, MA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Belmont

    Convenient for MA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Belmont site if eligible
  4. 4Begin participation

About This Major Depressive Disorder Study in Belmont

Stress and a parental history of major depressive disorder (MDD) are among the strongest risk factors for future development of MDD. Studies have shown that having a parental history of MDD may be associated with behavioral, psychophysiological, and hormonal responses to stress that are associated with poorer stress coping. . Adolescence is a vulnerable developmental window linked to increased MDD risk, especially for females, as rates of MDD surge relative to males. Despite the central role of stress in MDD onset, little is known about the brain mechanisms underlying stress responses in susceptible female adolescents at high familial risk for MDD. Also, it is unclear how stress-related brain network alterations may relate to "real-world" maladaptive stress responses and whether these stress-related brain network changes are predictive of future depression onset. We will fulfill these research gaps by combining neuroimaging with intensive longitudinal tracking of depressive symptomology as well as behavioral and physiological responses to "real world" stress using smartphone and smartwatch technology. Elucidating these neural mechanisms may aid in the discovery of MDD biomarkers that could identify youth at greatest risk for future MDD development and lead to earlier intervention efforts.

Sponsor: Mclean Hospital

Who Can Participate

Inclusion Criteria

General Inclusion Criteria for all Adolescent Cohorts:
Female sex assigned at birth
English as first language or English Fluency
Right-handed
Have a personal cell phone to complete the ecological momentary assessments
Ability to give signed, informed consent/assent either written or electronic (via RedCap eConsent)
Normal or corrected to normal vision and hearing Additional Inclusion Criteria for Female Adolescents with a Parental History of MDD, high-risk group: • A biological parent meeting DSM-5 criteria for at least one past/current major depressive episode

Exclusion Criteria

General Exclusion Criteria for all Adolescent Cohorts: • Presence of any contraindication for MRI:
Cardiac pacemakers
Metal clips on blood vessels (also called stents)
Artificial heart valve, artificial arms, hands, legs, etc.
Brain stimulator devices
Implanted drug pumps
Ear or eye implants
Known metal fragments in eyes
Exposure to metal filings or shrapnel (sheet metal workers, welders, and others)
Other metallic surgical hardware in vital area
Certain tattoos with metallic ink
Certain intrauterine devices (IUDs) containing metal
Any other metallic objects that are deemed a contraindication to MRI that cannot be removed
Certain transdermal (skin) patches such as: NicoDerm (nicotine for tobacco dependence) Transderm Scop (scopolamine for motion sickness) Ortho Evra (birth control)
Presence of medical or neurological illness that could impact fMRI measures of cerebral blood flow (e.g., head injury resulting in loss of consciousness greater than 5 minutes, seizure, tic disorder, serious/unstable cardiac, hepatic, renal, respiratory, endocrine, neurologic or hematologic illnesses)
Clinical/Laboratory Evidence of Hypothyroidism or Hyperthyroidism
Use of hormonal replacement therapy, anabolic steroids
Lifetime history of electroconvulsive therapy
Current tobacco product use
Lifetime use of any psychotropic medication
Clinically significant levels of depressive symptoms according to the Children's Depression Rating Scale-Revised (T Score \> 54, Poznanski et al., 1996)
Diagnosis of a neurodevelopmental disorder (e.g., Autism Spectrum Disorder, Learning Disorder w/ impairment in reading) that would interfere with study tasks (e.g., understanding and completing lengthy battery of questionnaires, ability to complete fMRI scan session and tasks without moving) Additional Exclusion Criteria for Female Adolescents with a Parental History of MDD, high-risk group: • Lifetime or current Diagnostic and Statistical Manual (DSM)-5 diagnoses of MDD, persistent depressive disorder, schizophrenia spectrum or other psychotic disorder, bipolar disorder, substance/alcohol use disorder, eating disorders, and posttraumatic stress disorder Additional Exclusion Criteria for Female Adolescents without a Parental History of MDD, low-risk group:
Any past or current Diagnostic and Statistical Manual (DSM)-5 psychiatric or substance/alcohol use disorder
First-degree relative history of any psychiatric disorder

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Belmont?

Yes, this clinical trial (NCT06816329) has an active research site in Belmont, MA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Major Depressive Disorder Treatment Options in Belmont, MA

If you're searching for major depressive disorder treatment options in Belmont, MA, this clinical trial (NCT06816329) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Belmont research site is actively enrolling participants for this clinical trial. You'll receive care from experienced major depressive disorder specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all major depressive disorder clinical trials near you to find additional studies recruiting in your area.

More Depression Trials in Belmont, MA

See all depression clinical trials recruiting in Belmont — not just this study.

Browse Depression Trials in Belmont →

Ready to Join in Belmont?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Belmont, MA